Matches in Wikidata for { <http://www.wikidata.org/entity/Q90417890> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- Q90417890 description "article scientifique publié en 2018" @default.
- Q90417890 description "artículu científicu espublizáu en xunetu de 2018" @default.
- Q90417890 description "scientific article published on 20 July 2018" @default.
- Q90417890 description "wetenschappelijk artikel" @default.
- Q90417890 description "наукова стаття, опублікована в липні 2018" @default.
- Q90417890 name "Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy tria" @default.
- Q90417890 name "Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy tria" @default.
- Q90417890 type Item @default.
- Q90417890 label "Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy tria" @default.
- Q90417890 label "Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy tria" @default.
- Q90417890 prefLabel "Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy tria" @default.
- Q90417890 prefLabel "Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy tria" @default.
- Q90417890 P1433 Q90417890-F3AE9A47-F4D0-4CD3-9835-462E71EA8747 @default.
- Q90417890 P1476 Q90417890-E1C0F4A7-C453-4CFE-9FC5-7B9D387EE6AE @default.
- Q90417890 P2093 Q90417890-03AABC6B-BC58-4945-BE92-BAAD1A98AA3B @default.
- Q90417890 P2093 Q90417890-188070C2-B75B-48CB-8AF5-0C13275060DD @default.
- Q90417890 P2093 Q90417890-2BF45C0F-B0ED-43C4-8AF4-002F47AE854C @default.
- Q90417890 P2093 Q90417890-3F27DFE3-AC2F-4602-869E-646AD63CFB94 @default.
- Q90417890 P2093 Q90417890-50F4CD83-766F-4B04-A728-873542A91368 @default.
- Q90417890 P2093 Q90417890-6C9E365F-2395-4686-8A5D-847BCA337DAC @default.
- Q90417890 P2093 Q90417890-6EDF9BC7-3EC6-49CA-A75E-B45D4C2EDB26 @default.
- Q90417890 P2093 Q90417890-BECCEA23-1BEE-4C83-A180-79A2430091AF @default.
- Q90417890 P2093 Q90417890-DA60E080-D42F-47D7-9608-BF2906204884 @default.
- Q90417890 P2093 Q90417890-E0F448E7-7F41-4C3C-84B1-FAF4E4FF8C54 @default.
- Q90417890 P2093 Q90417890-E28449BD-67DC-401E-AB66-B1D8B5A8C86D @default.
- Q90417890 P2093 Q90417890-E28C664C-C63A-4E52-B92F-C4793D183B1C @default.
- Q90417890 P2093 Q90417890-E93654A5-7177-4925-83AF-D313A6DE0AD2 @default.
- Q90417890 P304 Q90417890-D7E9246C-54CB-4065-9186-4CCBC67190FF @default.
- Q90417890 P31 Q90417890-DAAE81E0-ACC4-42D9-A389-479E026374A4 @default.
- Q90417890 P356 Q90417890-330D0A97-F7CA-4974-86E0-1C49AFE44BE2 @default.
- Q90417890 P478 Q90417890-F46E38FD-109F-4880-A350-452C816D8466 @default.
- Q90417890 P50 Q90417890-E35D80EE-E852-423A-8EBC-DEBAE98131DD @default.
- Q90417890 P577 Q90417890-C8DCCF50-C23F-4243-BF79-F48A9820B950 @default.
- Q90417890 P698 Q90417890-C2DEF9DA-CD9F-468F-AE82-13C11BFA0CF6 @default.
- Q90417890 P921 Q90417890-1BCA7926-A716-4B95-A163-0198EDDDAB66 @default.
- Q90417890 P921 Q90417890-5B35BF47-CE8A-4BE4-89E5-7696CB763C83 @default.
- Q90417890 P921 Q90417890-6EA0B578-C44D-44F2-A820-6629BD2E4724 @default.
- Q90417890 P921 Q90417890-72B83153-34BB-4FF1-87D6-BF1D4B70CD77 @default.
- Q90417890 P356 J.EJCA.2018.06.015 @default.
- Q90417890 P698 30036739 @default.
- Q90417890 P1433 Q332260 @default.
- Q90417890 P1476 "Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial" @default.
- Q90417890 P2093 "Andrea Tannapfel" @default.
- Q90417890 P2093 "Anke Reinacher-Schick" @default.
- Q90417890 P2093 "Birgitta Killing" @default.
- Q90417890 P2093 "Christian A Lerchenmüller" @default.
- Q90417890 P2093 "Dirk Arnold" @default.
- Q90417890 P2093 "Georg Dietrich" @default.
- Q90417890 P2093 "Jan Hertel" @default.
- Q90417890 P2093 "Reinhard Depenbusch" @default.
- Q90417890 P2093 "Salah-Eddin Al-Batran" @default.
- Q90417890 P2093 "Stefanie Nöpel-Dünnebacke" @default.
- Q90417890 P2093 "Susanna Hegewisch-Becker" @default.
- Q90417890 P2093 "Thoralf Lange" @default.
- Q90417890 P2093 "Ullrich Graeven" @default.
- Q90417890 P304 "105-113" @default.
- Q90417890 P31 Q13442814 @default.
- Q90417890 P356 "10.1016/J.EJCA.2018.06.015" @default.
- Q90417890 P478 "101" @default.
- Q90417890 P50 Q90417886 @default.
- Q90417890 P577 "2018-07-20T00:00:00Z" @default.
- Q90417890 P698 "30036739" @default.
- Q90417890 P921 Q108566365 @default.
- Q90417890 P921 Q188874 @default.
- Q90417890 P921 Q413299 @default.
- Q90417890 P921 Q422327 @default.